Indegene Limited has announced that its wholly owned subsidiary, Indegene Ireland Limited, has signed a definitive Share Purchase Agreement (SPA) to acquire 100% equity in BioPharm Parent Holding, Inc. and its subsidiaries (together referred to as BioPharm). The deal, valued at up to USD 106 million, is an all-cash transaction subject to cash and net working capital adjustments, and is expected to be completed on October 1, 2025.
BioPharm, headquartered in New Hope, Pennsylvania, is a data-driven healthcare marketing and communications agency that partners with Life Sciences companies in the North American region. Founded in August 2014, the company has built a strong reputation for delivering healthcare provider marketing solutions and employs more than 90 professionals. For the year ending December 2024, BioPharm reported revenues of USD 38.13 million (unaudited).
Indegene clarified that this acquisition does not fall under related-party transactions and that no promoter or promoter group has any interest in the deal. The acquisition is part of Indegene’s strategic plan to strengthen its omnichannel marketing agency business and expand its global capabilities in the Life Sciences sector.
Commenting on the development, the company stated that the addition of BioPharm will enhance Indegene’s service offerings for Life Sciences clients by integrating data-driven marketing expertise with its existing digital-first healthcare solutions.
The acquisition consideration includes a performance- and milestone-based component, and the transaction will be completed entirely in cash.